A GROUP OF HUMAN TUMOR CELL STRAINS HAS BEEN IDENTIFIED THAT IS MORE SENSITIVE TO GROWTH INHIBITION PRODUCED BY HUMAN INTERFERON THAN ARE OTHER TUMOR CELL STRAINS OR NORMAL HUMAN FIBROBLASTS.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3012
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Applied Genetics Inc.
205 Buffalo Ave., Freeport, NY, 11520
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DANIEL B. YAROSH
PRINCIPAL INVESTIGATOR
(516) 868-9026
Business Contact:
() -
Research Institution:
n/a
Abstract
A GROUP OF HUMAN TUMOR CELL STRAINS HAS BEEN IDENTIFIED THAT IS MORE SENSITIVE TO GROWTH INHIBITION PRODUCED BY HUMAN INTERFERON THAN ARE OTHER TUMOR CELL STRAINS OR NORMAL HUMAN FIBROBLASTS. THIS GROUP OF TUMOR STRAINS, DESIGNATED THE MER-PHENOTYPE, SHARES A BIOCHEMICAL DEFECT IN DNA REPAIR. THESE STRAINS MAY PROVE USEFUL AS THE BASIS FOR A RAPID, SENSITIVE, AND RELIABLE BIOASSAY FOR ANTITUMOR ACTIVITIES OF MANUFACTURED INTERFERONS. RESULTS FROM PHASE I RESEARCH ARE EXPECTED TO ESTABLISH MEASURES FOR INTERFERON INHIBITION OF CELL GROWTH, COLONY FORMING ABILITY, DNA SYNTHESIS, AND ORNITHINE DECARBOXYLASE ACTIVITY IN SEVERAL MER-STRAINS. PHASE II RESEARCH WILL FOCUS ON THE USE OF THE ASSAY IN ISOLATION AND CHARACTERIZATION OF INTERFERONS FROM NATURAL AND RECOMBINANT DNA SOURCES, AND IN THE USE OF THE MER-PHENOTYPE AS A MARKER FOR INTERFERON SENSITIVITY OF HUMAN TUMORS. THIS RESEARCH MAY BE APPLIED COMMERCIALLY IN THE PREPARATION OF INTERFERON AND MEDICALLY IN THE

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government